Europe rues SVB loss as a cornerstone life science supporter
With deeps links to the US likely severed, and HSBC’s risk appetite unknown, what does a future without Silicon Valley Bank look like?
Flotations versus blank cheques
Neither route to the stock market covered itself in glory in the recent bull market. But how do returns really stack up?
The ink dries on the blank cheque craze
As Apexigen throws in the towel six months after listing, can any bright spots be found in the stats on Spacs?
Biopharma’s venture year ends with another dip
Last year saw plenty of cash deployed, but with sums shrinking each quarter the stage is set for further retrenchment.
Evaluate Vantage 2023 Preview: free to download now
After a tough time for many in biopharma, what does 2023 hold for the sector? Find out in our preview of the year ahead.
